FDA rejects tibolone as menopause treatment in US

Published: 5-Jun-2006

The US Food & Drug Administration (FDA) has decided not to approve tibolone as a menopause treatment in the US. The decision is a disappointment to Akzo Nobel which has been marketing the drug in countries outside the US for nearly 20 years.


The US Food & Drug Administration (FDA) has decided not to approve tibolone as a menopause treatment in the US. The decision is a disappointment to Akzo Nobel which has been marketing the drug in countries outside the US for nearly 20 years.

Akzo's human healthcare business unit Organon, which filed an amendment to the NDA with the FDA in December 2005, plans to withdraw the application for tibolone.

"Although Organon is disappointed with the FDA's response, we will continue to be committed to this proven brand," said Toon Wilderbeek, general manager of Organon and member of Akzo Nobel's Board of Management responsible for Pharma.

You may also like